On March 6, 2024 Syncromune, Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ platform combination therapy optimized for solid tumor cancers, reported that it will present late-breaking Phase 1 clinical data at this year’s American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024, being held in San Diego, California from April 5 to 10, 2024 (Press release, Syncromune, MAR 6, 2024, View Source [SID1234640868]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, titled, "Systemic responses to SYNC-T therapy: in situ personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC)," will include results from the SV-102 Phase 1 trial, and the therapy’s potential impact on the treatment landscape for metastatic castrate-resistant prostate cancer. This late-breaking presentation marks the first time that the Company will have publicly shared data from its clinical trials of the SYNC-T therapy platform.

Presentation Details are:

Title: Systemic responses to SYNC-T therapy: in situ personalized cancer vaccination with intratumoral infusion of multitarget immunotherapy in patients with metastatic castrate-resistant prostate cancer (mCRPC)

Presenter: Charles J. Link, M.D.

Date: April 7, 2024

Time: 3:00 – 5:00pm PT

Session Title: Cancer Vaccines: Ready for Prime Time?

Location: San Diego Convention Center, San Diego, California